Join us for a virtual R&D Event with Medigene AG. The company’s leadership team will be discussing their exciting pipeline expansion into neoantigens and the evolution of Medigene’s end-to-end platform, focused on developing differentiated, best-in-class T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications.

Attendees are invited to listen to the presentations and panel discussion exploring the unmet needs in the treatment of solid tumors.

A live question and answer session will follow the formal presentations and discussions.